Close Menu

NEW YORK — The Pulmonary Fibrosis Foundation (PFF) said on Wednesday that it has partnered with Bristol-Myers Squibb subsidiary Celgene to launch a research consortium to identify biomarkers of pulmonary fibrosis that can guide therapy.

The foundation noted that the biomarkers would be directed at the development of treatments for patients with idiopathic pulmonary fibrosis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.